DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

Phase 2

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Osivelotor

First Posted Date: 2022-11-30

Last Posted Date: 2025-04-20

Lead Sponsor: Pfizer

Target Recruit Count: 47

Registration Number: NCT05632354

Locations: 🇺🇸
Our Lady of the Lake Hospital, Inc., Baton Rouge, Louisiana, United States
🇺🇸
University Medical Center New Orleans, New Orleans, Louisiana, United States
🇺🇸
Mississippi Center for Advanced Medicine, Madison, Mississippi, United States

and more 5 locations

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Maplirpacept
Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2022-11-23

Last Posted Date: 2025-02-13

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT05626322

Locations: 🇺🇸
Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States

and more 4 locations

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Daratumumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2022-11-21

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 1116

Registration Number: NCT05623020

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan
🇦🇺
Pindara Private Hospital, Benowa, Queensland, Australia

and more 60 locations

A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People

Completed

Conditions: COVID-19

Interventions: Biological: BNT162b2

First Posted Date: 2022-11-17

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 260

Registration Number: NCT05621239

Locations: 🇮🇩
Pfizer, Jakarta, Indonesia

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Phase 3

Recruiting

Conditions: Hemophilia A
Hemophilia B

Interventions: Drug: marstacimab

First Posted Date: 2022-11-10

Last Posted Date: 2024-12-24

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT05611801

Locations: 🇺🇸
Intermountain - Primary Children's Hospital, Salt Lake City, Utah, United States
🇦🇷
Arbesu Hematología, Mendoza, Argentina
🇦🇺
Sydney Children's Hospital, Randwick, New South Wales, Australia

and more 61 locations

Ngenla Subcutaneous Injection Special Investigation

Active, not recruiting

Conditions: Growth Hormone Deficiency Without Epiphyseal Closure

Interventions: Drug: NGENLA (Somatrogon)

First Posted Date: 2022-11-02

Last Posted Date: 2025-05-14

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05602766

Locations: 🇯🇵
Pfizer, Tokyo, Japan

Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

Recruiting

Conditions: Metastatic ALK+ Non Small Cell Lung Cancer

Interventions: Drug: Lorviqua

First Posted Date: 2022-10-31

Last Posted Date: 2025-03-12

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT05599412

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment

Completed

Conditions: Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Interventions: Drug: Inotuzumab Ozogamicin

First Posted Date: 2022-10-27

Last Posted Date: 2025-02-04

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT05597085

Locations: 🇮🇳
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, Delhi, India
🇮🇳
Fortis Memorial Research Institute, Gurugram, Haryana, India
🇮🇳
Tata Medical Center, Kolkata, WEST Bengal, India

and more 2 locations

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Completed

Conditions: Breast Cancer
Breast Carcinoma
Breast Neoplasms
Breast Tumors
Cancer of Breast

Interventions: Drug: Palbociclib plus hormonal treatment - first line treatment
Drug: Palbociclib plus hormonal treatment - second line treatment

First Posted Date: 2022-10-18

Last Posted Date: 2023-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 150

Registration Number: NCT05584644

Locations: 🇮🇳
HCG Cancer Centre, Ahmedabad, Gujarat, India, India
🇮🇳
Bhagwan Mahaveer Cancer Hospital and Research Centre, Bajaj Nagar, Jaipur, Rajasthan, India, India
🇮🇳
Hemato Oncology Clinic Ahmedabad Private Limited, Rajpath Club Lane ,Gujarat, India, Ahmedabad, India

and more 2 locations

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

Phase 3

Active, not recruiting

Conditions: Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo

Interventions: Drug: Placebo
Drug: Ritlecitinib

First Posted Date: 2022-10-17

Last Posted Date: 2025-02-27

Lead Sponsor: Pfizer

Target Recruit Count: 581

Registration Number: NCT05583526

Locations: 🇨🇳
The First Hospital of China Medical University/Dermatology and STD Department, Shenyang, Liaoning, China
🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
🇪🇸
Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Canarias, Spain

and more 107 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy